Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia

Background: Although oral atypical antipsychotics have improved the outcomes in schizophrenia, the patient medication adherence plays role as the important factor to clinical potential of the drugs. Therefore, the long-acting formulations of antipsychotics have been developed to improve the treatmen...

Full description

Saved in:
Bibliographic Details
Main Authors: Arunpongpaisal S., Srisurapanont M., Kongsakon R., Kitiwattanagul K., Samanwongthai U.
Format: Journal
Published: 2017
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77951895519&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/43339
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-43339
record_format dspace
spelling th-cmuir.6653943832-433392017-09-28T06:54:49Z Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia Arunpongpaisal S. Srisurapanont M. Kongsakon R. Kitiwattanagul K. Samanwongthai U. Background: Although oral atypical antipsychotics have improved the outcomes in schizophrenia, the patient medication adherence plays role as the important factor to clinical potential of the drugs. Therefore, the long-acting formulations of antipsychotics have been developed to improve the treatment compliance in patient with schizophrenia and risperidone long-acting injection (RLAI) is the first long-acting injectable drug since then. Objective: To evaluate the efficacy and tolerability of long-acting risperidone injection in Thai patients with chronic schizophrenia for 12 weeks treatment. Material and Method: This was a non-randomized, open-label, single-arm study, performed at 5 centers in Thailand. The eligible patients with schizophrenia diagnosed by DSM-IV criteria were enrolled. Patients received long-acting risperidone injection 25, 37.5 or 50 mg every 2 weeks. Efficacy assessments were measured by Manchester Psychiatric Rating Scale (MPS), CGI-S and SF-36 at baseline, week 6 and week 12 or end point visit. Tolerability assessments were measured by Yale Extrapyramidal Symptoms Rating Scale (YESS), Visual analogue scale 10-cm for pain at injection site, body weight (BW) and incidence of adverse events. Results: Of 184 patients recruited, 160 patients (87%) completed the study. RLAI produced a significant improvement (p < 0.001) in MPS positive score from baseline to endpoint, 4.4 + 3.7 to 1.6 + 2.6. There was also significant reduction in MPS negative score, from 3.06 + 2.68 to 0.93 + 1.61 at endpoint (p < 0.001). The CGI-S score improved significantly from baseline to end point (p < 0.001), as reflected by the increase the proportion of patients rated as "not ill" or "borderline ill" from 5.9% at baseline to 53.2% at endpoint. Quality of life measured on the SF-36 scale was improved in all domains except bodily pain. Movement disorders, measured by YESS, were significantly reduced following RLAI introduction. Treatment with this drug was well tolerated and no significant weight gain occurred during the study. Conclusion: This study suggests that RLAI produces symptomatic improvement in chronic schizophrenia patients, along with improvement of movement disorders and had a good tolerability and adherence to treatment. 2017-09-28T06:54:48Z 2017-09-28T06:54:48Z 2010-03-01 Journal 01252208 2-s2.0-77951895519 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77951895519&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/43339
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
description Background: Although oral atypical antipsychotics have improved the outcomes in schizophrenia, the patient medication adherence plays role as the important factor to clinical potential of the drugs. Therefore, the long-acting formulations of antipsychotics have been developed to improve the treatment compliance in patient with schizophrenia and risperidone long-acting injection (RLAI) is the first long-acting injectable drug since then. Objective: To evaluate the efficacy and tolerability of long-acting risperidone injection in Thai patients with chronic schizophrenia for 12 weeks treatment. Material and Method: This was a non-randomized, open-label, single-arm study, performed at 5 centers in Thailand. The eligible patients with schizophrenia diagnosed by DSM-IV criteria were enrolled. Patients received long-acting risperidone injection 25, 37.5 or 50 mg every 2 weeks. Efficacy assessments were measured by Manchester Psychiatric Rating Scale (MPS), CGI-S and SF-36 at baseline, week 6 and week 12 or end point visit. Tolerability assessments were measured by Yale Extrapyramidal Symptoms Rating Scale (YESS), Visual analogue scale 10-cm for pain at injection site, body weight (BW) and incidence of adverse events. Results: Of 184 patients recruited, 160 patients (87%) completed the study. RLAI produced a significant improvement (p < 0.001) in MPS positive score from baseline to endpoint, 4.4 + 3.7 to 1.6 + 2.6. There was also significant reduction in MPS negative score, from 3.06 + 2.68 to 0.93 + 1.61 at endpoint (p < 0.001). The CGI-S score improved significantly from baseline to end point (p < 0.001), as reflected by the increase the proportion of patients rated as "not ill" or "borderline ill" from 5.9% at baseline to 53.2% at endpoint. Quality of life measured on the SF-36 scale was improved in all domains except bodily pain. Movement disorders, measured by YESS, were significantly reduced following RLAI introduction. Treatment with this drug was well tolerated and no significant weight gain occurred during the study. Conclusion: This study suggests that RLAI produces symptomatic improvement in chronic schizophrenia patients, along with improvement of movement disorders and had a good tolerability and adherence to treatment.
format Journal
author Arunpongpaisal S.
Srisurapanont M.
Kongsakon R.
Kitiwattanagul K.
Samanwongthai U.
spellingShingle Arunpongpaisal S.
Srisurapanont M.
Kongsakon R.
Kitiwattanagul K.
Samanwongthai U.
Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia
author_facet Arunpongpaisal S.
Srisurapanont M.
Kongsakon R.
Kitiwattanagul K.
Samanwongthai U.
author_sort Arunpongpaisal S.
title Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia
title_short Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia
title_full Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia
title_fullStr Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia
title_full_unstemmed Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia
title_sort risperidone long-acting injection (rlai): the 12-week efficacy and tolerability in thai patients with chronic schizophrenia
publishDate 2017
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77951895519&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/43339
_version_ 1681422359286775808